SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Win McNamee/Getty Images
Business
BMS CEO Earned $20 Million in 2020, a 7% Increase Amidst a Global Pandemic
In his fifth year as CEO, his take-home was about $20.15 million – an almost $1.7 million base pay plus $13.5 million in stock awards, with another $5 million in incentive plan pay with “other” pay.
March 26, 2021
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Immuno-Oncology Treatments Finding Success with Combination Therapies
With oncology drugs clocking a disheartening 3.4% success rate, some good news in the field is always appreciated.
March 25, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: March 17-23
It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
March 23, 2021
 · 
6 min read
 · 
Kate Goodwin
News Brief – FDA Slapdown, Patent Approval, Funding News and More
The life sciences industry is a bustling beehive of activity. Here’s a quick compilation of some of today’s newsworthy announcements.
March 23, 2021
 · 
3 min read
 · 
Kate Goodwin
Life Sciences Industry Becomes Latest Arena in Hackers’ Digital Warfare
A global pandemic has left life sciences companies with giant targets on their backs for cyberattacks.
March 23, 2021
 · 
4 min read
 · 
Kate Goodwin
Drug Development
Odonate Pulls MBC Drug Candidate Tesetaxel and Closes Shop
After touting “positive results” in December and August for its Phase III cancer drug, Tesetaxel, Odonate Therapeutics is now discontinuing drug development and closing up shop.
March 22, 2021
 · 
1 min read
 · 
Kate Goodwin
Money on the Move: March 10-16
Life sciences money is seemingly growing on trees this year. Here’s who picked a good harvest this week.
March 16, 2021
 · 
5 min read
 · 
Kate Goodwin
Business
ExeVir Snags $50 Million to Take Llama Antibody into First In-Human Trials
German shepherds take down bad guys, dalmatians pull people from fires, beagles sniff out bombs and now llamas fight COVID-19.
March 16, 2021
 · 
2 min read
 · 
Kate Goodwin
Michael Bailey, CEO / Courtesy of AVEO Oncology
Business
AVEO Reclaims Full Global Rights to Antibody Drug from CANbridge
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
March 15, 2021
 · 
2 min read
 · 
Kate Goodwin
Four Biotechs Bringing Home the Bacon for Cancer Therapies, Vaccines and MRSA
Investment dollars continue to flood the life sciences industry as new technologies and groundbreaking approaches tear down the dams that have previously hindered advancement.
March 12, 2021
 · 
4 min read
 · 
Kate Goodwin
Image courtesy of Getty Images
Takeda Takes on the World with Big Growth Plans for the Decade
The Japanese pharma giant is aiming for double-digit revenue growth of its Growth and Emerging Markets Business Unit (GEM BU) by 2030. Here’s how they plan to do it.
March 11, 2021
 · 
2 min read
 · 
Kate Goodwin
Deals
Are SPACs Better Than Traditional IPOs?
Here’s the scoop on IPO versus SPAC (Special Purpose Acquisition Corporation) from Paul Mieyal, life sciences investment guru.
March 10, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Money on the Move – March 3-9
Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week.
March 9, 2021
 · 
4 min read
 · 
Kate Goodwin
Drug Development
Antibody Drug Fails to Beat Placebo in Trial for Rare Inflammatory Skin Condition
AnaptysBio started the week with some disappointing news for its lead antibody drug imsidolimab.
March 8, 2021
 · 
1 min read
 · 
Kate Goodwin
KemPharm CEO Travis Mickle/Courtesy KemPharm
FDA
KemPharm Snags Approval for ADHD Prodrug
KemPharm announced this week that the U.S. Food and Drug Administration has approved its novel ADHD drug for use in patients six years and older.
March 4, 2021
 · 
2 min read
 · 
Kate Goodwin
Load More